Evaluation of drug utilisation pattern and cost associated with diabetes mellitusType 2 management in Saudi Arabia
DOI:
https://doi.org/10.1590/s2175-97902022e20681Keywords:
Antidiabetic Agents, Diabetes Mellitus Type 2, Drug Utilisation Pattern, Defined Daily Dose, Cost analysis, Saudi ArabiaAbstract
Diabetic mellitus is an emerging disease in Saudi Arabia. In this regard, a cross-sectional retrospective study was conducted to evaluate drug utilization pattern and the cost associated with non-insulin-dependent diabetes mellitus disease management in Saudi Arabia. Data retrieved from the electronic pharmacy records during the last one year were employed in this study. World Health Organization (WHO) Defined Daily Dose (DDD) method was employed to compute the daily price of each oral hypoglycaemic agent. The American Diabetes Association (ADA) guidelines and protocols were used to evaluate the level of adherence. A total of 17057 patients were enrolled in the study. Out of the 17057 patients enrolled in the study, 60.06 % (10246) were males and the rest females. In monotherapy, biguanides (metformin) were the most recommended and utilised drugs among 5673 patients (33.25%). The most commonly used drug combination was found to be sitagliptin+metformin (1754 units). The cost per unit dose was highest for liraglutide (A10BJ02) 258.32SR (68.79USD), and lowest for metformin (A10BA02) 0.49SR (0.13 USD). Metformin was the choice drug for the diabetes patients; biguanides (metformin) and DPP-4 (sitagliptins) were the most familiar established dose combination employed. Generic drugs should be used in order to reduce overall cost
Downloads
References
Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: A prospective, cross-sectional study at a tertiary care teaching hospital. J Basic Clin Pharm. 2013;4(4):82-7.
Alhowaish A. Economic costs of diabetes in Saudi Arabia. J Family Community Med. 2013;20(1):1-7.
Alzaid A. Diabetes: a tale of two cultures. Br J Diabetes Vasc Dis. 2012;12:57.
American Diabetes Association. Oral medication: What are my options? Oral medication: What are my options? https://www.diabetes.org/diabetes/medication-management/oral-medication/what-are-my-options [Assess on 4th June 2020].
» https://www.diabetes.org/diabetes/medication-management/oral-medication/what-are-my-options
American Diabetes Association. Introduction: Standards of medical care in diabetes 2020. Diab. Care. 2020;43(Suppl.1):S1-S2. https://care.diabetesjournals.org/content/43/Supplement_1/S1 [Assess on 4th June 2020].
» https://care.diabetesjournals.org/content/43/Supplement_1/S1
Andayani T, Imaningsih I. Cost analysis of antidiabetic drugs for diabetes mellitus outpatient in Kodya Yogyakarta Hospital. Malay J Phar Sci. 2007;5(1):19-23.
Arnetz L, Ekberg NR, Alvarsson M. Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Syndr Obes. 2014;7:409-420.
ATC/DDD Index 2020 ATC/DDD Index 2020 https://www.whocc.no/atc_ddd_index/ [Assess on 4th June 2020].
» https://www.whocc.no/atc_ddd_index/
Cong JY, Zhao Y, Xu QY, Zhong CD, Xing QL. Health-related quality of life among Tianjin Chinese patients with type 2 diabetes: a cross-sectional survey. Nurs Health Sci. 2012;14(4):528-34.
Davari M, Bayazidi Y, Esteghamati A, Larijani B, Kebriaeezadeh A. The prescription pattern of antidiabetic medication and glycemic control in type 2 diabetes in Iran: a patient level study. Diabetes Manag. 2019;9(2):57-65.
Eibich P, Green A, Hattersley AT, Jennison C, Lonergan M, Pearson ER, et al. Costs and treatment pathways for Type 2 diabetes in the UK: A mastermind cohort study. Diabetes Ther. 2017;8(5):1031-45.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diab Care. 1997;20:1183-97.
Hill SR. Cost-effectiveness analysis for clinicians. BMC Medicine 2012;10:10. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avandamet/pdf/AVANDAMET-PI-MG.PDF [Assess on 4th June 2020]
International Diabetes Federation. IDF Diabetes Atlas, 9th ed. Brussels, Belgium: International Diabetes Federation; 2019. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.htm [Assess on 4th June 2020].
» https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.htm
Johnson JA, Pohar SL, Secnik K, Yurgin N, Hirji Z. Utilization of diabetes medication and cost of testing supplies in Saskatchewan. BMC Health Serv Res. 2006;6:159.
Meo SA, Usmani AM, Qalbani E. Prevalence of type 2 diabetes in the Arab world: impact of GDP and energy consumption. Eur Rev Med Pharmacol Sci. 2017;21(6):1303-1312.
Misbahuddin MR, Hussam AM, Zohair JG, Ziaullah MS. Anti-diabetic drugutilization patterns in a government hospital in Saudi Arabia. Trop JPharm Res. 2018;17(6):1193-200.
Mokdad AH, Tuffaha M, Hanlon M, El Bcheraoui C, Daoud F, Al Saeedi, et al. Cost of Diabetes in the Kingdom of Saudi Arabia, 2014. J Diabetes Metab. 2015;6(8):575.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2009;32(1):193-203.
Nordström A, Hadrévi J, Olsson T, Franks PW, Nordström P. Higher Prevalence of Type 2 Diabetes in Men Than in Women Is Associated With Differences in Visceral Fat Mass. J Clin Endocrinol Metab. 2016;101(10):3740-6.
Okoro RN, Nmeka C, Erah PO. Utilization study of antidiabetes medicines at a tertiary care hospital in Nigeria. Future J Pharm Sci. 2018;4(2):109-115.
Rafeeq M M, Murad H. Evaluation of drug utilization pattern for patients of bronchial asthma in a government hospital of Saudi Arabia. Niger J Clin Pract. 2017;20(9):1098-105.
Sathananthan A, Vella A. Personalized pharmacotherapy for Type 2 diabetes mellitus. Per Med. 2009;6(4):417-422.
Satpathy SV, Datta S, Upreti B. Utilization study of antidiabetic agents in a teaching hospital of Sikkim and adherence to current standard treatment guidelines. J Pharm Bioall Sci. 2016;8(3):223-8.
Scollan-Koliopoulos M, Bleich D, Rapp KJ, Wong P, Hofmann CJ, Raghuwanshi M. Health-related quality of life, disease severity, and anticipated trajectory of diabetes. Diabetes Educ. 2013;39(1):83-91.
Shah K, Solanki N, Rana D, Acharya K. Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: A prospective, cross-sectional study at a tertiary care teaching hospital. J Basic Clin Pharm . 2013;4(4):82.
Sharma S, Tandon VR, Roshi Mahajan A. Prescribing pattern of oral antihyperglycaemic drugs, rationality and adherence to American Diabetes Association (ADA) treatment guidelines among type 2 diabetes mellitus (T2DM) postmenopausal women. J Clin Diagn Res. 2016;10(1):11-5.
Van Tilburg J, van Haeften TW, Pearson P, Wijimenga C. Defining the genetic contribution of type 2 diabetes mellitus. J Med Genet. 2001;38(9):569-578.
Vijayakumar TM, Jayram J, Meghana Cheekireddy V, Himaja D, Dharma Teja Y, Narayanasamy D. Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review. Curr Ther Res Clin Exp. 2017;84:4-9.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care . 2004;27(5):1047-1053.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
